Drug intelligence / Profile preview

LNT 1

Development stage: Preclinical
Lead developer: Tocris
Modality: Small Molecules
Administration: Not Applicable (research Use Only; Not Approved For Clinical Administration)

Overview

LNT 1 is a potent small molecule inhibitor of flap endonuclease 1 (FEN1), an enzyme involved in DNA replication and repair. It exhibits high selectivity for FEN1 (IC50 = 46.4 nM for hFEN1-336Δ) and is cytotoxic to SW620 colorectal cancer cells in vitro by inducing a DNA damage response. The compound has been used as a research tool to study synthetic genetic interactions of human FEN1 with DNA damage response genes and has demonstrated the ability to induce replication arrest, intra S-phase checkpoint activation, and apoptosis in glioma stem cells[1][3][8].

Other names: LNT 1LNT1LNT-1FEN1-IN-1FEN-1-IN-1FEN 1-IN-1

Targets

FEN1 (Flap endonuclease 1)

Beyond the preview

Go deeper on LNT 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNT 1.

Explore the full profile